Theratechnologies Inc T.TH

New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

Poster highlightsdurable disease stabilization lasting beyond treatment completionResults suggest a unique, multimodal mechanism of action that differs from other cancer therapeuticsFavorable tolerability sets stage for Part 3 (dose optimization) of Phase 1 trial, already underway MONTREAL...read article.

[palinc2000]

QWERTY Can you comment and or add colour ?

[juniper88]

I won't pretend to know the science as qwerty or scarlett would know.  But from a patient's point of view getting 45 weeks of stable disease at this late stage is quite something.  And from being in the clinic and going over treatment options with the oncologist, it sounds better than most options at this late stage.  

[Trogarzon]

Very encouraging news... I think this is major.

[muslix1]

tk god to hit me... finally a good news for THTX

[scarlet1967]

Apart from the clinical efficacy they are talking about and lower concentration of  free doxetaxel one thing which they are "suggesting" and I found it interesting is the "multimodal" aspects  of the drug. Note all those MOS's listed in the PR were preclinical findings and now they are considered to be responsible for those clinical results!! In a

[Qwerty54321]

So my initial thoughts revolve around the MOA too. Both positive and negative or should I say still full of questions. You are right about the multi MOA coming from the preclinical work but I don't think you can quite say they are now seeing those actions in the clinical data. What I'd say they are doing is laying the clinical data next to the preclinical finding and "encouraging

[Saurus100]

Usually, they are doing their best to keep the information confidential until the day of the event. Often, results are announced  at that time, specially first phase....  Why, between May 2nd (press release) and now, have they changed their mind?   The initial press release stated that the information will be presented on June 1st... Why releasing the highlights now? Why at 5pm

[ANALIAS00]

Nobody seems to care !!   That is weird. 

[SPCEO1]

Unfortunately, the leadership team has burned through nearly all of their credibility. So, while there was good news in that press release, few are even reading it and fewer still are going to react to it. THTX needs to announce something that has real dollars attached to it (like a partnership for TH-1902) to get investors to take a look at what they are doing. It sounds like anything like that

[Mannequin]

I am aware that of some staff in the oncology group in the UK are attending the upcoming ASCO sessions. I've passed along the latest release. However unless the management has personally tried to reach out, then they will be sitting waiting for someone to show up. The company really needs to be say more, explain more and get out there. 

[Mannequin]

I forgot to say who I sent it to.  It was GSC.  Some staff have in the research group have been made aware of 1902 by me over the past year but without them having any concrete, they do not know what is really up.

[Qwerty54321]

Analias, I don't really think these result are a strong indicator of either the path this drug is going to take through clinical trials from this point onwards or even the utility of the drug. I'd say that's the problem still. For example There's two things here. 1) The SORT1 delivery system (where the patents lie) 2) This version of the drug with docetaxel It may be that the

[SPCEO1]

JFM - hoping you are still doing well and that you are up to offering your thoughts on the latest press release.

[jfm1330]

Hey, I wrote something just as you were posting this. Some telepathy I guess!!!

[jfm1330]

Stable disease for many years is a very good outcome on advanced patients. Take my word for that. That being said, approval through progression free survival (PFS) takes much longere than through tumor shrinkage, partial response or complete response. So they are in for the long run if results are good enough. That's why they will need a partner and they will have to sell a big part of the

[SPCEO1]

Thanks JFM! You doindeed know of what you speak - may you go from stability to restored health!

[Qwerty54321]

Certainly stable disease is a great thing for individual patients but it is how you develop a clinical trial program and where the drug ends up fitting into the clinic in terms of other drugs on the market while decide the value of this to us, THTX and any partner. That's a harder call, certainly for me, at this moment. I guess Jfm is hinting at that. This is a big part of the ongoing

[jfm1330]

If all they have on humans is stable disease, even on half of the patients, it will be hard to attract a partner, again, because it means the long and costly road to approval and they have nothing else to show proof of concept. So hopefully they can have a few partial responses or some biomarkers data. I don't know if there is a proven biomarker to assess evolution of ovarian cancer. In the

[SPCEO1]

I am glad there are other treatment options for you but sad to hear of your declining quality of life. You have battled this beast for a very long time and I am sure it takes an emotional as well as physical toll. I doubt many of us would have had the stamina you have shown. And thanks for keeping an eye on this board in the midst of that and weighing in with your always helpful insights. I would

[jfm1330]

Thanks for your good words and thoughts SPCEO. I hope you are recovering well from your own health problems.

[SPCEO1]

I don't know if I really feel like I recovered asI felt fine before getting my stents, the procedure placing the stents was a breeze and I have felt fine ever since. The only improvement I have noticed is I don't sweat as much as before when doing somethign physical. I really never felt bad, just had some relatively minor twinges in my right pec which was the only indication my body was

[Momo25]

To JFM3030, I wish full recovery. Just keep fighting this beast as much as you can!

[juniper88]

The biomarker for ovarian cancer is CA-125. With my wife after 1 infusion of TH1902 it dropped by over 40%.  I remember Dr. Winers assistant coming back to us with a smile.  We were very happy.  But my wife had 2 stents placed in her liver and pancreas.  They became infected and that is why she died.  Also because so much time was wasted and she had become so weak. 

[Mannequin]

It is sad it potentially could have helped, and I wonder if anyone else in her situation has been put through the program with ovarian cancer and seen any benefit. There is not much explained thus far, but Soleus did top up at the financing. It makes me wonder if they had access to more data than we have, and if so, hmmm.    

[Mannequin]

The cannot start a Ga68 trial without evidence. Coupling a clinical trial with Ga-68 (Gallium-68) involves using this radioisotope in conjunction with a PET scan to enhance the imaging and diagnostic capabilities within the trial. Here’s an overview of what this would entail and its feasibility: What it Entails Radiotracer Development: Ga-68 can be linked to specific molecules or

[jfm1330]

The strong scientific rationale was there from the beginning. A company with real financial means and stong scientific people would have integrated it in their clinical protocol from the beginning. I agree that now it's too late for that. It could be implemented just if they end up having good enough results and a great partner. Again, it's like F4 and F8 for tesamorelin, they had these

[Mannequin]

As they have FDA Fast Track, do you think there is any leniency at the FDA for amending the trial (with a partner who has experience) to add Ga68 without having to start the trial from scratch?  if there is, then that's the pitch to a partner however I just wonder if they could get one without the need to give up the entire platform; or most of the upside.     

[Trogarzon]

Just get upfront to pay back the Shylock and get double digit on whatever comes out of this drug.  That simple.

[jfm1330]

I don't know if they can attract a partner. That being said, a big pharma like Bristol Myers Squibb now has this expertise. They bought RayzeBio for 4.1 B$ and their main drug candidate is 225 Ac-Dotatate. So it is the same thing as Lutathera, but with Actinium-225 instead of Lutetium-177. Lutathera is owned by Novartis. So big pharmas are willing to par to enter in this therapeutic field

[ANALIAS00]

Thank you....for everything !!